Silence Therapeutics plc (NASDAQ:SLN) Short Interest Update

Silence Therapeutics plc (NASDAQ:SLN) saw a large increase in short interest during the month of March. As of March 15th, there was short interest totalling 92,700 shares, an increase of 100.6% from the February 29th total of 46,200 shares. Based on an average daily trading volume, of 241,500 shares, the short-interest ratio is presently 0.4 days.

Silence Therapeutics Trading Down 1.0 %

Shares of Silence Therapeutics stock traded down $0.22 on Thursday, hitting $21.60. 116,304 shares of the company’s stock traded hands, compared to its average volume of 259,416. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.56 and a quick ratio of 4.56. Silence Therapeutics has a one year low of $4.55 and a one year high of $27.72. The firm’s 50-day moving average price is $22.58 and its two-hundred day moving average price is $15.72. The stock has a market capitalization of $646.44 million, a PE ratio of -14.79 and a beta of 1.45.

Institutional Trading of Silence Therapeutics

Several hedge funds have recently added to or reduced their stakes in SLN. SG Americas Securities LLC bought a new stake in shares of Silence Therapeutics during the fourth quarter worth $110,000. Citadel Advisors LLC acquired a new position in Silence Therapeutics in the 2nd quarter valued at $136,000. Geode Capital Management LLC lifted its holdings in shares of Silence Therapeutics by 17.2% during the second quarter. Geode Capital Management LLC now owns 17,207 shares of the company’s stock worth $95,000 after buying an additional 2,520 shares in the last quarter. Millennium Management LLC grew its stake in shares of Silence Therapeutics by 19.8% in the fourth quarter. Millennium Management LLC now owns 17,436 shares of the company’s stock valued at $266,000 after acquiring an additional 2,879 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC acquired a new stake in Silence Therapeutics in the 4th quarter worth about $450,000. Institutional investors and hedge funds own 98.73% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on SLN shares. Chardan Capital upped their target price on Silence Therapeutics from $26.00 to $42.00 and gave the stock a “buy” rating in a research report on Thursday, March 14th. HC Wainwright reaffirmed a “buy” rating and set a $75.00 price objective on shares of Silence Therapeutics in a research report on Friday, March 15th. BMO Capital Markets began coverage on Silence Therapeutics in a research note on Wednesday, January 31st. They issued an “outperform” rating and a $67.00 price objective on the stock. Finally, Morgan Stanley increased their price target on Silence Therapeutics from $29.00 to $45.00 and gave the company an “overweight” rating in a report on Thursday, March 14th.

About Silence Therapeutics

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.